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THE INCIDENCE OF DEEP VEINthrombosis (DVT) is1per1000person-years.1The10-yearrecur-rence risk is 30%.2 Deep vein
thrombosis can lead to life-threatening
pulmonaryembolism.3Deepveinthrom-
bosis is caused by acquired and genetic
riskfactors.Acquiredriskfactors include
age, hospitalization, cancer, pregnancy,
hormone therapy, and surgery.2 Family
andtwinstudies indicatethatgeneticsac-
countsforabout60%oftheriskforDVT.4,5
Deficienciesofnaturalanticoagulantsan-
tithrombin, proteinC, and protein S are
strongrisk factors forDVT;however, the
variantscausingthesedeficienciesarerare
and explain only about 1%of all DVTs.6
Twomorecommongeneticvariants,Fac-
tor V Leiden (FVL) and prothrombin
G20210A,havebeenconsistently found
tobeassociatedwithDVT7,8butstillonly
explain a fraction of the DVT events.6 It
hasbeensuggestedthat2ormoreriskfac-
tors are needed for thrombosis.6,9,10
The identification of additional com-
mon gene variants associatedwithDVT
will improve the ability to predict risk
for DVT and increase understanding of
this disease. Therefore, we investigated
whether any of 19 682 primarily mis-
sense single-nucleotide polymor-
phisms (SNPs) were associated with
DVT in 3 large case-control studies.
METHODS
Study Populations
and Data Collection
The 3 studies (LETS, MEGA-1 and
MEGA-2) in the present analysis are de-
rived from 2 large population-based
case-control studies: the LeidenThrom-
bophilia Study (LETS)11 and the Mul-
tiple Environmental and Genetic As-
sessment of Risk Factors for Venous
Thrombosis (MEGA study).12 These
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Context The genetic causes of deep vein thrombosis (DVT) are not fully under-
stood.
Objective To identify single-nucleotide polymorphisms (SNPs) associated with DVT.
Design, Setting, and Patients We used 3 case-control studies of first DVT. A total
of 19 682 gene-centric SNPs were genotyped in 443 cases and 453 controls from the
Leiden Thrombophilia Study (LETS, 1988-1992). Twelve hundred six SNPs associated
with DVT were reinvestigated in the Multiple Environmental and Genetic Assessment
of Risk Factors for Venous Thrombosis study (MEGA-1, 1999-2004) in a subset of 1398
cases and 1757 controls. Nine SNPs associated with DVT in both LETS and MEGA-1
were investigated a third time in 1314 cases and 2877 controls from MEGA-2, a sec-
ond subset of MEGA. Additional SNPs close to one SNP in CYP4V2 were genotyped
in LETS and MEGA-1.
Main Outcome Measure Odds ratios (ORs) for DVT were estimated by logistic
regression. False discovery rates served to investigate the effect of multiple hypoth-
esis testing.
Results Of 9 SNPs genotyped in MEGA-2, 3 were strongly associated with DVT
(P .05; false discovery rate.10): rs13146272 inCYP4V2 (risk allele frequency, 0.64),
rs2227589 in SERPINC1 (risk allele frequency, 0.10), and rs1613662 in GP6 (risk al-
lele frequency, 0.84). The OR for DVT per risk allele was 1.24 (95% confidence in-
terval [95%CI], 1.11-1.37) for rs13146272, 1.29 (95%CI, 1.10-1.49) for rs2227589,
and 1.15 (95% CI, 1.01-1.30) for rs1613662. In the region of CYP4V2, we identified
4 additional SNPs (in CYP4V2, KLKB1, and F11) that were also associated with both
DVT (highest OR per risk allele, 1.39; 95% CI, 1.11-1.74) and coagulation factor XI
level (highest increase per risk allele, 8%; 95% CI, 5%-11%).
Conclusions We identified SNPs in several genes that were associated with DVT.
We also found SNPs in the region around the SNP in CYP4V2 (rs13146272) that were
associated with both DVT and factor XI levels. These results show that common ge-
netic variation plays an important role in determining thrombotic risk.
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studies were approved by the Medical
Ethics Committee of the Leiden Uni-
versity Medical Center, Leiden, the
Netherlands. All participants gave oral
informed consent for LETS and writ-
ten for MEGA to participate.
LETS Population
Collection and ascertainment of DVT
events in LETS has been described pre-
viously.11 Briefly, 474 consecutive pa-
tients, 70 years or younger, without a
known malignancy were recruited be-
tween January 1, 1988, and December
30, 1992, from 3 anticoagulation clin-
ics in the Netherlands. For each pa-
tient, an age- and sex-matched con-
trol participant without a history of
DVT was enrolled. Participants com-
pleted a questionnaire on risk factors
for DVT and provided a blood sample.
No ethnicity information was col-
lected. After exclusion of 52 partici-
pants due to inadequate sample, 443
cases and 453 controls remained in the
analyses.
MEGA-1 and MEGA-2 Studies
Collection and ascertainment of DVT
events in MEGA has been described
previously.12,13 MEGA enrolled con-
secutive patients aged 18 to 70 years
who presented with their first diagno-
sis of DVT or pulmonary embolism
(PE) at any of 6 anticoagulation clin-
ics in the Netherlands between March
1, 1999, and May 31, 2004. Control
subjects included partners of patients
and random population control sub-
jects frequency-matched on age and sex
to the patient group. Participants com-
pleted a questionnaire on risk factors
for DVT and provided a blood or buc-
cal swab sample. The questionnaire in-
cluded an item on parent birth coun-
try as a proxy for ethnicity.
For the present analyses, we split the
MEGA study to form 2 case-control
studies, based on recruitment date and
sample availability (blood or buccal
swab). We excluded those with iso-
lated pulmonary embolism or a his-
tory of malignant disorders to obtain a
study population similar to that of the
LETS population. The first subset,
MEGA-1, included1398 cases and1757
controls who all donated a blood
sample. The remaining 1314 cases and
2877 controls who donated either a
blood sample or a buccal swab sample
were included in MEGA-2.
SNP Association Study
The 19682 SNPs tested in this study are
located in 10 887 genes and were se-
lected because of their potential to affect
gene function or expression.14 Most
SNPs (69%) aremissense. Another 24%
of the SNPs are located in transcrip-
tion factor binding sites or in untrans-
lated regions of mRNA, which could
affectmessenger RNAexpression or sta-
bility. Ninety-one percent of the SNPs
studied have minor allele frequencies
of at least 5% inwhites. Information on
all SNPs tested and primer sequences
are available on request.
The design of the SNP association
study is presented in the FIGURE. First,
all 19 682 SNPs were tested in pooled
DNA samples of LETS (http://www
.ncbi.nlm.nih.gov/projects/SNP).
Single-nucleotide polymorphisms that
were associated with DVT (P .05)
were tested in pooled DNA samples of
MEGA-1. Single-nucleotide polymor-
phisms that were associated in both
LETS andMEGA-1pools (P .05)were
confirmed by genotyping individual
samples of LETS andMEGA-1. Single-
nucleotide polymorphism genotypes
consistently associated with DVT in
LETS and MEGA-1 (P .05) were
genotyped in MEGA-2 .
Allele Frequency and Genotype
Determination
DNA concentrations were standard-
ized to 10 ng/µL using PicoGreen (Mo-
lecular Probes, Invitrogen Corp, Carls-
bad, California) fluorescent dye. DNA
pools, typically of 30 to 100 samples,
were assembled based on case-control
Figure. Flowchart of the Approach Used to Identify SNPs Associated With Deep Vein
Thrombosis
No. of SNPs genotyped Sample
S TA G E  1
S TA G E  2
S TA G E  3
S TA G E  4
No. of SNPs associated with
deep vein thrombosis (P< .05)
19 682 SNPs
1206 SNPs
LETS pooled DNA samples
443 Cases
453 Controls
1206 SNPs
104 SNPs
MEGA-1 pooled DNA samples
1398 Cases
1757 Controls
104 SNPs
18 SNPs
LETS and MEGA-1
Genotyping of individual samples
9 SNPs a
3 SNPs
MEGA-2
Genotyping of individual samples
1314 Cases
2877 Controls
LETS indicates Leiden Thrombophilia Study; MEGA, Multiple Environmental and Genetic Assessment of Risk
Factors for Venous Thrombosis; and SNP, single-nucleotide polymorphism.
aOnly 9 SNPs were subsequently tested in MEGA-2 because assays for the other 9 were not available.
GENE VARIANTS AND DEEP VEIN THROMBOSIS
©2008 American Medical Association. All rights reserved. (Reprinted) JAMA, March 19, 2008—Vol 299, No. 11 1307
 by guest on May 11, 2011jama.ama-assn.orgDownloaded from 
status, sex, age, and factor V Leiden sta-
tus. DNA pools were made by mixing
equal volumes of standardizedDNA so-
lution from each individual sample.
Each allele was amplified separately by
polymerase chain reaction (PCR) using
3 ng of pooled DNA. In the pooled
stage, we used 6 case pools and 4 con-
trol pools for LETS, and 13 case pools
and 18 control pools for MEGA-1. Al-
lele frequencies in pooledDNAwere de-
termined by kinetic polymerase chain
reaction (kPCR).15 Duplicate kPCR as-
sayswere run for each allele and the am-
plification curves from these assays
were used to calculate the allele fre-
quencies of the SNP.15 Genotyping of
individual DNA samples was similarly
performed using 0.3 ng of DNA in
kPCR assays15 or using multiplexed
oligo ligation assays.16 Genotyping ac-
curacy of the multiplex method and
kPCR has been assessed in 3 previous
studies, and the overall concordance of
the genotype calls from these 2 meth-
ods was greater than 99%.14,17,18 The
SNPs associated with DVT inMEGA-2
were successfully genotyped in more
than 95% of the participants in LETS,
MEGA-1, and MEGA-2.
Gene Variants and DVT Risk
in the CYP4V2 Region
Thers13146272SNPinthegeneCYP4V2
wasmost strongly associatedwithDVT
in the SNP association study. To inves-
tigatewhetherother SNPs in this region
areassociatedwithDVT,weusedresults
from the HapMap Project19 to identify
aregionsurroundingrs13146272(chro-
mosome4:187,297,249-187,467,731).
This regioncontained149SNPswithal-
lele frequencies ofmore than2%(Hap-
MapNCBIbuild36).Allele frequencies
and linkagedisequilibriumwere calcu-
latedfromtheSNPgenotypes intheHap-
MapCentred’EtudeduPolymorphisme
Humain (CEPH)population,which in-
cludesUtahresidentswithancestry from
northern and western Europe. We se-
lected48of these149SNPs forgenotyp-
ing,assurrogates for142of the149SNPs
in this region that were either directly
genotypedor in strong linkagedisequi-
librium (r20.8) with at least 1 of the
48 genotyped SNPs (the remaining 7of
the 149 SNPs were in low-linkage dis-
equilibriumwith rs13146272 (r20.2)
and therefore not likely to be the cause
oftheobservedassociation).The48SNPs
were chosen using pairwise tagging in
Tagger (implemented inHaploview20).
The 48 SNPs were initially investi-
gated in LETS, and SNPs that were
equally ormore strongly associatedwith
DVT than rs13146272 were investi-
gated in MEGA-1.
Factor XI Assays
FactorXI antigenmeasurements inLETS
were described previously.21 In MEGA,
factor XI levels were measured on a
STA-R coagulation analyzer (Diagnos-
tica Stago, Asnières, France). STA cal-
cium chloride solution was used as an
activator, STAUnicalibratorwas used as
a reference standard, and Preciclot plus
I (normal factor XI range) was used as
control plasma. The intraassay coeffi-
cient of variation was 5.8% (10 assays).
The interassaycoefficientofvariationwas
8.7% (48 assays).
Statistical Analysis
Deviations from Hardy-Weinberg ex-
pectations were assessed using an ex-
act test in controls.22 For pooled DNA
analysis, a Fisher exact test was used
to evaluate allele frequency differ-
ences between cases and controls. For
the final set of SNPs, logistic regres-
sion models were used to calculate the
odds ratio (OR), 95% confidence in-
terval (95%CI), and 2-sided P value for
the association of each SNP with DVT
and to adjust for age and sex. For each
SNP, we calculated the OR per geno-
type relative to noncarriers of the risk
allele, and the risk allele OR from an
additive model. This risk allele OR can
be interpreted as the risk increase per
copy of the risk allele, and the corre-
sponding P value was used to decide
whether the SNP was associated with
DVT (P .05). For SNPs on theX chro-
mosome the analysis was conducted
separately in men and women.
The OR (95% CI) for SNPs in the
CYP4V2 region was estimated by
logistic regression with adjustment for
factor XI levels and other SNPs in the
region. Differences in factor XI level
between groups were tested with t
tests, and changes in factor XI level
per allele were estimated by linear
regression.
Analyses were done using SAS ver-
sion 9 (SAS Institute Inc, Cary, North
Carolina) and SPSS for Windows,
14.0.2 (SPSS Inc, Chicago, Illinois).
False Discovery Rate
Studies of thousands of SNPs can lead
to false-positive associations. There-
fore, we performed 2 replications after
the initial discovery stage in LETS and
calculated the false discovery rate for
the SNPs genotyped in MEGA-2. The
false discovery rate estimates the ex-
Table 1. Characteristics of Cases and Controls in LETS, MEGA-1, and MEGA-2
No. (%) of Participants
LETS MEGA-1 MEGA-2
Cases
(n = 443)
Controls
(n = 453)
Cases
(n = 1398)
Controls
(n = 1757)
Cases
(n = 1314)
Controls
(n = 2877)
Men 190 (43) 192 (42) 652 (47) 843 (48) 633 (48) 1348 (47)
Age, mean (SD), y 45 (14) 45 (14) 47 (13) 48 (12) 48 (13) 47 (12)
Both parents born in northwestern Europea 1247 (91) 1609 (92) 1149 (90) 2527 (89)
Abbreviations: LETS, Leiden Thrombophilia Study; MEGA, Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis.
aNo information on birth country was collected in LETS.
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pected fraction of false positives among
a group of SNPs; and is a function of
the P values and the number of tests.23
False discovery rates were estimated
using the 2-sided, unadjusted P value
from the additive model. We used a
false discovery rate of 0.10 as a crite-
rion for further analysis (for a false dis-
covery rate of 0.10, one would expect
Table 2. Association of 18 SNPs From the SNP Association Study and Factor V Leiden and Prothrombin G20210A With Deep Vein Thrombosis
in the LETS and MEGA-1 Studiesa
Chromosome Gene
SNP
Study
Risk
Allele
No. (%) of Alleles
OR (95% CI)c
P
ValueIdentification Typeb Cases Controls
3 NR1I2 rs1523127 5UTR LETS C 373 (42) 300 (33) 1.44 (1.19-1.73) .001
MEGA-1 1185 (42) 1373 (39) 1.15 (1.04-1.27) .008
19 GP6 rs1613662 Ser219Pro LETS A 749 (85) 725 (80) 1.36 (1.07-1.74) .01
MEGA-1 2318 (84) 2823 (81) 1.21 (1.06-1.38) .004
17 APOH rs1801690 Ser335Trp LETS C 850 (97) 852 (95) 1.65 (1.02-2.68) .04
MEGA-1 2676 (96) 3312 (94) 1.42 (1.12-1.79) .004
2 NAT8B rs2001490 Ala112Gly LETS C 382 (43) 348 (38) 1.23 (1.01-1.49) .04
MEGA-1 1118 (40) 1301 (37) 1.14 (1.03-1.26) .01
1 SERPINC1 rs2227589 Intronic LETS T 105 (12) 78 (9) 1.42 (1.04-1.94) .03
MEGA-1 303 (11) 313 (9) 1.24 (1.05-1.47) .01
7 MET rs2237712 Intronic LETS G 45 (5) 27 (3) 1.68 (1.05-2.70) .03
MEGA-1 119 (4) 110 (3) 1.38 (1.06-1.80) .02
11 EPS8L2 rs3087546 Leu101Leu LETS T 522 (60) 487 (54) 1.26 (1.04-1.52) .02
MEGA-1 1637 (59) 1964 (56) 1.12 (1.01-1.24) .03
6 CASP8AP2 rs369328 Lys93Lys LETS A 461 (52) 406 (45) 1.35 (1.11-1.63) .002
MEGA-1 1420 (51) 1680 (48) 1.13 (1.02-1.24) .02
1 SELP rs6131 Asn331Ser LETS T 196 (22) 161 (18) 1.29 (1.03-1.62) .03
MEGA-1 589 (21) 636 (18) 1.21 (1.06-1.36) .003
19 ZNF544 rs6510130 Asp203His LETS G 33 (4) 13 (1) 2.54 (1.34-4.83) .004
MEGA-1 78 (3) 64 (2) 1.56 (1.11-2.18) .01
1 RGS7 rs670659 Intronic LETS C 617 (70) 584 (64) 1.27 (1.04-1.54) .02
MEGA-1 1864 (67) 2249 (64) 1.13 (1.01-1.25) .03
2 TACR1 rs881 3UTR LETS C 745 (85) 713 (80) 1.38 (1.07-1.77) .01
MEGA-1 2356 (85) 2894 (83) 1.15 (1.01-1.32) .04
4 CYP4V2 rs13146272 Lys259Gln LETS A 611 (69) 588 (65) 1.22 (1.00-1.49) .05
MEGA-1 1896 (68) 2245 (64) 1.19 (1.07-1.32) .001
1 F5 rs4524 Arg858Lys LETS T 708 (80) 671 (74) 1.36 (1.09-1.69) .006
MEGA-1 2184 (79) 2608 (74) 1.26 (1.12-1.42) .001
1 SMOYKEEBO/F5 rs6016 Ile736Ile LETS G 704 (80) 668 (74) 1.35 (1.09-1.69) .006
MEGA-1 2188 (79) 2615 (75) 1.27 (1.13-1.43) .001
1 C1orf114 rs3820059 Ser172Phe LETS A 320 (36) 269 (30) 1.34 (1.10-1.64) .004
MEGA-1 1065 (38) 1169 (33) 1.22 (1.10-1.35) .001
X F9 rs6048 Ala194Thr LETS Men A 146 (77) 128 (67) 1.74 (1.10-2.74) .02
LETS Women 225 (70) 238 (68) 1.09 (0.84-1.42) .50
MEGA-1 Men 464 (73) 566 (68) 1.26 (1.00-1.58) .05
MEGA-1 Women 674 (72) 818 (71) 1.04 (0.90-1.21) .61
X ODZ1 rs2266911 Intronic LETS Men C 161 (85) 147 (77) 1.66 (0.99-2.79) .06
LETS Women 422 (83) 418 (80) 1.26 (0.91-1.73) .17
MEGA-1 Men 556 (85) 671 (80) 1.47 (1.12-1.94) .006
MEGA-1 Women 1234 (82) 1430 (78) 1.25 (1.05-1.48) .01
1 F5 (Leiden) rs6025 Arg534Gln LETS A 95 (11) 14 (2) 7.19 (4.05-12.77) .001
MEGA-1 291 (10) 96 (3) 4.10 (3.23-5.21) .001
11 F2 (G20210A) rs1799963 3UTR LETS A 28 (3) 10 (1) 2.98 (1.43-6.20) .001
MEGA-1 81 (3) 37 (1) 2.89 (1.94-4.29) .001
Abbreviations: CI, confidence interval; LETS, Leiden Thrombophilia Study; MEGA, Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study; OR,
odds ratio, SNP, single-nucleotide polymorphism.
aAll gene symbols, rs numbers, SNP types, and chromosome numbers are from the National Center for Biotechnology Information build 36.
bThe first amino acid corresponds to the nonrisk allele.
cORs were estimated by logistic regression using an additive model. Sex was included as a covariate in logistic regression models containing markers residing on the X chromosome and
the number of risk alleles for these SNPs were coded as 0 or 1 for males and 0, 1, or 2 for females.
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10% of the SNPs in the group consid-
ered associated to be false positives).
RESULTS
Baseline characteristics of the partici-
pants are presented in TABLE 1.
SNPs Associated With DVT
in LETS and MEGA-1
In LETS, we investigated 19 682 SNPs
by comparing the allele frequencies of
patients and controls using pooledDNA
samples.15We found that 1206 of these
19 682 SNPs were associated (P .05)
with DVT. These 1206 SNPs were then
investigated in patients and controls
from MEGA-1 using pooled DNA
samples. The SNPs that were associ-
ated with DVT in both LETS and
MEGA-1 were confirmed by genotyp-
ing in both studies, and we found that
18 SNPs were consistently (with the
same risk allele) associated with DVT
(P .05) in both LETS and MEGA-1
(TABLE 2).
SNPs Associated with DVT
in MEGA-2
Nine of these 18 SNPs were subse-
quently tested in MEGA-2 for associa-
tionwithDVT (TABLE 3); assays for the
other 9 SNPs were not available at the
time. The genotypes of these 9 SNPs did
not deviate from the Hardy-Weinberg
equilibrium (P .01) in the LETS and
MEGA controls.
To account for themany tests, we es-
timated the false discovery rate for the
SNPs tested inMEGA-2. In Table 2, fac-
tor V Leiden and the prothrombin
G20210A mutation are presented for
reference. Because these variants were
not included in the SNP association
study, we did not calculate their false
discovery rate. For the SNP in F9
(rs6048), we only included men be-
cause in women, no association with
DVT was observed in LETS and
MEGA-1. We found that 3 SNPs were
again associated with DVT inMEGA-2
(P .05), with false discovery rates
.10. These 3 SNPs were in the genes
CYP4V2, SERPINC1, and GP6. The 4
SNPs with the next lowest P values
(ranging from .06-.15) also had low
false discovery rates (.20). These SNPs
were in the genesRGS7,NR1I2,NAT8B,
and F9. The risk allele frequencies for
these 7 SNPs ranged from 11% to
82% among the controls. The OR for
homozygous carriers, compared with
homozygotes of the other allele, ranged
from 1.19 to 1.49. The 2 SNPs most
strongly associated with DVT were in
CYP4V2 (rs13146272, P .001, false
discovery rate 0.0006) and SERPINC1
(rs2227589, P .001, false discovery
rate, 0.004).
For the 2 SNPs on chromosome 1
(rs2227589 and rs670659), we inves-
tigated linkage disequilibrium with
FVL. The SNP (rs2227589) in SER-
PINC1, which encodes antithrombin, is
4.37 megabases away from the FVL
variant. The SNP in RGS7 (rs670659)
is 71.48megabases fromFVL. Eachwas
in weak linkage disequilibrium with
FVL (r2.01). Restricting analyses to
noncarriers of FVL did not apprecia-
bly change the risk estimate of either
SNP (data not shown).
SNPs in CYP4V2 Region
and DVT Risk
The SNP with the strongest associa-
tion with DVT was rs13146272, lo-
cated in the gene encoding a member
of the cytochrome P450 family 4
(CYP4V2). We genotyped 48 SNPs in
this region in the LETS population
(eTable available at http://www.jama
.com) and estimated the OR for DVT
per copy of the risk-increasing allele.
For many of the 48 SNPs, including
rs13146272, the common allelewas the
risk allele. In LETS, rs13146272 had an
OR for DVT of 1.22 (95% CI, 1.00-
1.49). Higher ORs were observed for 9
of the other SNPs tested in this region.
These SNPs were located in the
CYP4V2, KLKB1 (coding for prekal-
likrein), and F11 (coding for coagula-
tion factor XI) genes.
We then selected the 9 of the 48 SNPs
that had an OR of more than 1.22 (the
OR of rs13146272) and investigated
them inMEGA-1.We found that, in ad-
dition to rs13146272, four of these
SNPswere associatedwithDVT in both
LETS and MEGA-1: rs3087505,
rs3756008, rs2036914, and rs4253418
(TABLE 4). The rs3087505 SNP in
KLKB1 had the highest risk estimate:
OR 3.61 (95% CI, 1.48-8.82) for the
major allele homozygotes vs minor al-
lele homozygotes. Mutual adjustment
among these 5 SNPs did not indicate
that any of these 5 associationswere ex-
plained by the other 4 SNPs (data not
shown).
SNPs in CYP4V2 Region
and Factor XI Levels
Because the F11 gene is located close
to rs13146272 and because factor XI
levels have been previously reported to
be associated with DVT in the LETS
population,21 we investigated whether
an association between SNPs and fac-
tor XI levels explained the association
between the SNPs and DVT. In LETS,
factor XI levels above the 90th percen-
tile had been shown to be associated
with a 2-fold increased risk of DVT.21
We found that high factor XI levels
(90th percentile) were also associ-
atedwithDVT inMEGA (OR, 1.9; 95%
CI, 1.6-2.3).
The 5 SNPs from the CYP4V2 region
that were associated with DVT were all
associated with factor XI levels in LETS
andMEGA-1, with higher factor XI lev-
els for those who carried the risk-
increasing alleles (Table 4).We investi-
gated whether factor XI levels mediate
theassociationbetween these5SNPsand
DVT by adjusting for factor XI levels in
the combined LETS andMEGA-1 stud-
ies. For all 5 SNPs, adjustment for fac-
tor XI levels weakened the association
with DVT but none of the associations
disappeared. Interestingly, the 5 SNPs
thatwerenot associatedwithDVT in the
combinedanalysis of LETSandMEGA-1
(rs3736456, rs4253259, rs4253408,
rs4253325, andrs3775302)werealsonot
associatedwith factor XI levels in LETS.
All analyseswere performedwith and
without adjustment for age and sex, and
analyses inMEGA-1 andMEGA-2were
performed with and without restric-
tion to the groupwith bothparents born
in northwestern Europe. Because nei-
ther influenced the results, we pre-
sented the unadjusted OR.
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Table 3. Associations of SNPs From the SNP Association Study With Deep Vein Thrombosis in MEGA-2a
Chromosome Gene SNP
Risk
Alleleb Genotypec
No. (%) of Alleles
OR (95% Cl)
P
Value
False
Discovery RateeCased Controld
4 CYP4V2 rs13146272 A CC 121 (10) 352 (13) 1 [Reference]
.001 .001CA 478 (41) 1178 (45) 1.18 (0.94-1.49)
AA 561 (48) 1094 (42) 1.49 (1.19-1.88)
Additive (69) (64) 1.24 (1.11-1.37)
1 SERPINC1 rs2227589 T CC 1001 (77) 2325 (82) 1 [Reference]
.001 0.004CT 278 (21) 483 (17) 1.34 (1.13-1.58)
TT 15 (1) 28 (1) 1.24 (0.66-2.34)
Additive (12) (11) 1.29 (1.10-1.49)
19 GP6 rs1613662 A GG 29 (2) 89 (3) 1 [Reference]
.03 0.10GA 355 (27) 835 (29) 1.31 (0.84-2.02)
AA 915 (70) 1924 (68) 1.46 (0.95-2.24)
Additive (84) (82) 1.15 (1.01-1.30)
1 RGS7 rs670659 C TT 129 (10) 355 (13) 1 [Reference]
.06 0.13TC 615 (48) 1326 (47) 1.28 (1.02-1.60)
CC 548 (42) 1153 (41) 1.31 (1.04-1.64)
Additive (66) (64) 1.10 (1.00-1.22)
3 NR1I2 rs1523127 C AA 480 (37) 1097 (39) 1 [Reference]
.07 0.13AC 598 (46) 1340 (47) 1.02 (0.88-1.18)
CC 220 (17) 409 (14) 1.23 (1.01-1.50)
Additive (40) (38) 1.09 (0.99-1.20)
2 NAT8B rs2001490 C GG 490 (38) 1122 (39) 1 [Reference]
.12 0.18GC 603 (46) 1334 (47) 1.04 (0.90-1.19)
CC 205 (16) 394 (14) 1.19 (0.98-1.45)
Additive (39) (37) 1.08 (0.98-1.19)
X F9 (men) rs6048 A Additive (73) (70) 1.17 (0.94-1.445) .15 0.20
X F9 (women) rs6048 A GG 56 (8) 148 (10) 1 [Reference]
.37 NAGA 275 (41) 615 (41) 1.18 (0.84-1.66)
AA 343 (51) 752 (50) 1.21 (0.86-1.68)
Additive (71) (70) 1.07 (0.93-1.23)
19 ZNF544 rs6510130 G CC 1192 (95) 2626 (95) 1 [Reference]
.56 0.63CG 60 (5) 137 (5) 0.97 (0.71-1.32)
GG 0 (0) 4 (0) -
Additive (2) (3) 0.91 (0.67-1.24)
7 MET rs2237712 G AA 1183 (93) 2528 (93) 1 [Reference]
.79 0.79AG 86 (7) 184 (7) 1.00 (0.77-1.30)
GG 3 (0) 3 (0) 2.14 (0.43-10.6)
Additive (4) (4) 1.03 (0.80-1.33)
11 F2 rs1799963 A GG 1219 (94) 2794 (98) 1 [Reference]
.001 NAfGA 76 (6) 55 (2) 3.17 (2.22-4.51)
AA 0 (0) 0 (0) -
Additive (3) (1) 3.17 (2.22-4.51)
1 F5 rs6025 A GG 1029 (81) 2646 (95) 1 [Reference]
.001 NAfGA 235 (18) 140 (5) 4.32 (3.46-5.39)
AA 8 (0) 2 (0) 10.30 (2.18-48.52)
Additive (10) (3) 4.24 (3.42-5.26)
Abbreviations: CI, confidence interval; LETS, Leiden Thrombophilia Study; MEGA, Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study; NA, not
applicable, not in false discovery rate analysis; OR, odds ratio; SNP, single-nucleotide polymorphism.
aAll gene symbols and rs numbers are from the National Center for Biotechnology Information build 36.
bRisk-increasing allele identified in LETS and MEGA-1.
c In the additive model, the increase in risk per copy of the risk allele is calculated.
dFor the additive model, only the allele frequency is presented, not the count.
eP value from the additive model was used for false discovery rate estimation.
fFactor V Leiden and the prothrombin G20210A mutation are presented for reference. Because these variants were not included in the SNP association study, we did not calculate their
false discovery rate.
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COMMENT
We identified 7 SNPs that were asso-
ciated with DVT in 3 large, well-
characterized populations including
3155 cases and 5087 controls. The evi-
dence was strongest for the 3 SNPs in
theCYP4V2, SERPINC1, andGP6 genes.
It is interesting to note that these SNPs
are in or near genes that have a clear
role in blood coagulation. This may in-
dicate that the coagulation system is
well characterized.
Testing 19 682 SNPs will result in
false-positive associations. Therefore,
we investigated the SNPs in 3 large
studies and estimated the false discov-
ery rate for the SNPs tested in the third
study. The 3 SNPs in genes CYP4V2,
Table 4. Association of 10 SNPs in CYP4V2 Region With Deep Vein Thrombosis and Factor XI Levels in the Combined LETS and MEGA-1
Studies
SNP Gene
Risk
Allele Genotype
Risk Allele, No. (%) Factor XIa Deep Vein Thrombosis
Case Control % Difference (95% CI) OR (95% CI) OR (95% CI)b
rs13146272 CYP4V2 A CC 181 (10) 293 (13) 1 [Reference] 1 [Reference] 1 [Reference]
CA 808 (44) 995 (45) 3 (1 to 6) 1.32 (1.07 to 1.62) 1.26 (1.03 to 1.56)
AA 850 (46) 919 (42) 7 (4 to 9) 1.50 (1.22 to 1.84) 1.36 (1.10 to 1.68)
Additive (68) (64) 3 (2 to 4) 1.20 (1.09 to 1.31) 1.14 (1.04 to 1.25)
rs3736456c CYP4V2 T CC 7 (0) 0 (0)
CT 162 (9) 222 (10) 1 [Reference] 1 [Reference] 1 [Reference]
TT 1663 (91) 1973 (90) 1 (−1 to 4) 1.16 (0.93 to 1.43) 1.15 (0.93 to 1.42)
Additive (95) (95) 1 (−2 to 4) 1.06 (0.86 to 1.30) 1.05 (0.85 to 1.28)
rs3087505 KLKB1 C TT 6 (0) 25 (1) 1 [Reference] 1 [Reference] 1 [Reference]
TC 317 (17) 438 (20) 11 (6 to 16) 3.02 (1.22 to 7.44) 2.59 (1.05 to 6.40)
CC 1509 (82) 1743 (79) 19 (14 to 24) 3.61 (1.48 to 8.82) 2.81 (1.15 to 6.89)
Additive (91) (89) 8 (6 to 10) 1.27 (1.09 to 1.47) 1.15 (0.99 to 1.34)
rs4253259 KLKB1 C AA 5 (0) 6 (0) 1 [Reference] 1 [Reference] 1 [Reference]
AC 168 (9) 219 (10) 0 (−18 to 18) 0.92 (0.28 to 3.07) 0.95 (0.28 to 3.20)
CC 1652 (91) 1978 (90) 0 (−19 to 18) 1.00 (0.31 to 3.29) 1.03 (0.31 to 3.43)
Additive (95) (95) 0 (−3 to 2) 1.08 (0.88 to 1.32) 1.08 (0.88 to 1.32)
rs4253408 F11 A GG 1526 (83) 1869 (85) 1 [Reference] 1 [Reference] 1 [Reference]
GA 293 (16) 317 (14) 4 (2 to 6) 1.13 (0.95 to 1.35) 1.06 (0.89 to 1.27)
AA 15 (1) 17 (1) 13 (−1 to 27) 1.08 (0.54 to 2.17) 0.97 (0.48 to 1.98)
Additive (9) (8) 5 (3 to 7) 1.11 (0.95 to 1.30) 1.05 (0.89 to 1.23)
rs4253325 F11 G AA 21 (1) 23 (1) 1 [Reference] 1 [Reference] 1 [Reference]
AG 308 (17) 392 (18) 5 (0 to 16) 0.86 (0.47 to 1.58) 0.86 (0.46 to 1.59)
GG 1507 (82) 1785 (81) 8 (−3 to 13) 0.93 (0.51 to 1.68) 0.88 (0.48 to 1.62)
Additive (90) (90) 3 (1 to 5) 1.05 (0.91 to 1.21) 1.01 (0.87 to 1.17)
rs3775302 KLKB1 A GG 1418 (77) 1686 (77) 1 [Reference] 1 [Reference] 1 [Reference]
GA 380 (21) 481 (22) −1 (−3 to 1) 0.94 (0.81 to 1.09) 0.97 (0.83 to 1.13)
AA 38 (2) 34 (2) −4 (−11 to 3) 1.33 (0.83 to 2.12) 1.34 (0.83 to 2.14)
Additive (12) (12) −1 (−3 to 0) 1.00 (0.87 to 1.14) 1.02 (0.89 to 1.16)
rs3756008 F11 T AA 526 (29) 788 (36) 1 [Reference] 1 [Reference] 1 [Reference]
AT 903 (49) 1032 (47) 7 (6 to 9) 1.31 (1.14 to 1.51) 1.21 (1.04 to 1.39)
TT 408 (22) 384 (17) 15 (12 to 17) 1.59 (1.33 to 1.90) 1.32 (1.09 to 1.59)
Additive (47) (41) 7 (6 to 8) 1.27 (1.16 to 1.38) 1.16 (1.05 to 1.27)
rs2036914 F11 C TT 302 (17) 505 (23) 1 [Reference] 1 [Reference] 1 [Reference]
TC 895 (49) 1081 (49) 7 (5 to 9) 1.38 (1.17 to 1.64) 1.27 (1.07 to 1.51)
CC 633 (35) 620 (28) 14 (12 to 16) 1.71 (1.43 to 2.05) 1.43 (1.19 to 1.73)
Additive (59) (53) 7 (6 to 8) 1.30 (1.19 to 1.42) 1.19 (1.08 to 1.30)
rs4253418 F11 G AA 3 (0) 4 (0) 1 [Reference] 1 [Reference] 1 [Reference]
AG 120 (7) 199 (9) 14 (10 to 19) 0.80 (0.18 to 3.65) 0.69 (0.15 to 3.14)
GG 1710 (93) 2000 (91) 22 (18 to 26) 1.14 (0.26 to 5.10) 0.88 (0.20 to 3.94)
Additive (97) (95) 8 (5 to 11) 1.39 (1.11 to 1.74) 1.24 (0.99 to 1.56)
Abbreviations: CI, confidence interval; LETS, Leiden Thrombophilia Study; MEGA, Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study; NA, not
applicable, not in false discovery rate analysis; OR, odds ratio; SNP, single-nucleotide polymorphism.
aFactor XI level per genotype was calculated in controls.
bOR for deep vein thrombosis was adjusted for factor XI level.
cBecause there were no homozygotes for the C (protective) allele of rs3736456, the CT genotype was taken as reference group for the genotype OR.
GENE VARIANTS AND DEEP VEIN THROMBOSIS
1312 JAMA, March 19, 2008—Vol 299, No. 11 (Reprinted) ©2008 American Medical Association. All rights reserved.
 by guest on May 11, 2011jama.ama-assn.orgDownloaded from 
SERPINC1, and GP6 were associated
with DVTwith a false discovery rate of
less than 10%, which means that less
than 10% of these 3 SNPs would be ex-
pected to be false positive. Relaxing the
false discovery rate to less than 20%
would add 4 SNPs, in RGS7, NR1I2,
NAT8B, andF9 as associatedwithDVT.
The 3 SNPs with the strongest evi-
dence for associationwithDVTwere in
the genesCYP4V2, SERPINC1, andGP6.
TheCYP4V2 gene encodes amember of
the CYP450 family 4 that is not known
to be related to thrombosis.24,25 The
CYP4V2 gene is located on chromo-
some 4 in a region containing genes en-
coding coagulation proteins prekal-
likrein (KLKB1) and factorXI (F11).We
also found 4 other SNPs in theCYPV42/
KLKB1/F11 locus that were associated
with DVT. No previous reports exist of
genetic variants in CYP4V2 and KLKB1
and their association with DVT. There
exists no evidence for an association be-
tween prekallikrein levels and DVT,26
while there is evidence for elevated fac-
tor XI levels.4,21 It remains unclear
whether only one of these SNPs, or all
of them affect DVT risk.
The SERPINC1 gene encodes anti-
thrombin, a serine protease inhibitor lo-
cated on chromosome 1 that plays a
central role in natural anticoagula-
tion. Deficiencies of antithrombin are
rare but result in a strong thrombotic
tendency.26 The SNP in SERPINC1
(rs2227589) had a minor allele fre-
quency of about 10% in the controls and
was associated with a modest throm-
botic tendency. The GP6 gene en-
codes glycoprotein VI, a 58-kDa plate-
let membrane glycoprotein that plays
a crucial role in the collagen-induced
activation and aggregation of plate-
lets27 and may play a role in DVT.28
The SNPs in the genes F9, NR1I2,
RGS7, andNAT8B are of interest for fur-
ther validation. The F9 gene encodes
factor IX, a vitamin K–dependent co-
agulation factor, of which high levels
have been shown to increase the risk
of DVT.29 The SNP rs6048, also known
as F9 Malmo¨, is a common polymor-
phism at the third amino acid residue
of the activation peptide of factor IX.30
The SNP inCYP4V2 (rs13146272) is
located close to the gene encoding co-
agulation factor XI. Factor XI levels
have been reported to be associatedwith
DVT in LETS21 and in a large analysis
of pedigrees.4 We confirmed the asso-
ciation betweenDVT and factor XI lev-
els inMEGA. Interestingly, the 5 SNPs
in the CYP4V2 region that were asso-
ciated with DVT in both LETS and
MEGA-1were also associated with fac-
tor XI levels. However, the association
between these 5 SNPs and DVT does
not seem to be completely explained by
variation in factor XI levels because ad-
justing for factor XI level did not re-
move the excess DVT risk of these 5
SNPs. Thus, if only part of the risk as-
sociated with these genetic variants is
mediated through levels of factor XI,
some of the risk might also be due to
effects on protein function.
Several variants in the F11 gene
(rs5974, rs5970, rs5971, rs5966,
rs5976, and rs5973) were previously
tested for associationwith factor XI lev-
els in patients with DVT and athero-
sclerosis, but no relationship was ob-
served.31 In the present study, rs5974
(r2=1.0 with 5970) and rs5971 (r2=1.0
with 5966 and rs5976) were not asso-
ciated with DVT in LETS. Rs5973 was
not genotyped because its minor allele
frequency was lower than 2% (Hap-
Map CEPH population). In a study of
West African volunteers,32 rs3822056
and rs3733403 were associated with
transcription factor binding affinity and
slightly increased factor XI levels, but
neither SNP was associated with DVT
in LETS. In a study among white post-
menopausal women,33 rs3822057 and
rs2289252 were associated with DVT.
Both of these associations were indi-
rectly confirmed in the present study
because 2 of the 5 SNPs in theCYPV42
region that were consistently associ-
ated with DVT and factor XI levels are
in l inkage disequil ibrium with
rs3822057 (r2=0.9with rs2036914) and
rs2289252 (r2=0.8 with rs3756008).
The association between genetic vari-
ants and DVT may depend on clinical
variables or other risk factors for DVT,
such as surgery or the use of oral con-
traceptives. Because we aimed to iden-
tify variants that are associated with
DVT in general and from a large set of
SNPs, we did not study subgroups.
Clinical utility, however, may well de-
pend on interaction with these clini-
cal variables and should form a focus
of subsequent studies.
The associations between SNPs and
DVT were modest, for instance homo-
zygous carriership of the AA genotype
of rs13146272 inCYP4V2 increased risk
1.49-fold. However, because the vari-
ants are common, they might be use-
ful risk indicators especiallywhen com-
binedwith other risk factors.Moreover,
the associations found might repre-
sent a diluted effect of an unmeasured
SNP in linkage disequilibrium or indi-
cate a region with several variants in-
volved in DVT susceptibility. The re-
sults from theCYP4V2 region illustrate
the need for further study, because
some ORs found in that region were
higher than init ial ly found for
rs13146272.
Only 9 of 18 stage 3 SNPs were in-
deed tested in MEGA-2 DNA in stage
4. The reason for this was that in or-
der to saveMEGA-2DNA, stage 4 SNPs
were genotyped using multiplexed
oligoligation assays, and assays for
only 9 stage 3 SNPs were available at
the time of this study. Therefore, a fu-
ture extension of this study may yield
additional SNPs associated with DVT.
The replication criteria that we used
to identify SNPs associated with DVT
may have caused us to miss some truly
associated positive variants. Although
the statistical power to detect associa-
tions betweenDVT and uncommon ge-
netic variation was high, a rare variant
with a modest association with DVT
may have been missed.
Our analysis was limited to a north-
western European population. Con-
founding in a genetic study may arise
from population stratification, ie, the
presence of ethnic groups with differ-
ent allele anddisease frequencieswithin
a study. In LETS, no information on
ethnicity was collected. However, we
do not think that population stratifi-
cation biased our results becauseMEGA
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participants were recruited from the
same population as LETS but 10 years
later and 90% of MEGA had both par-
ents born in northwestern Europe. Fur-
thermore, restricting the analyses to this
90% of MEGA did not modify our re-
sults.
CONCLUSIONS
We tested thousands of SNPs for asso-
ciation with DVT in unrelated indi-
viduals, and found 7 genetic variants
consistently associatedwith risk. In the
CYP4V2 region we identified several
SNPs that were associated with both
DVT and factor XI levels. Although
most variants had a modest effect on
risk, they were common and could
therefore be responsible for as many
thrombotic events in the population as
stronger but rarer variants. Clinical util-
ity may stem from the determinants
being frequent and affecting many
people, aswell as from interactionswith
environmental risk factors (high-risk
situations) and interactions with other
genes. Subsequent studies will be
needed to further our knowledge on
these issues.
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